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ABSTRACT 
 
 Acrolein is an electrophilic α, β-unsaturated aldehyde. Additionally, acrolein is a 
metabolite of the antineoplastic alkylating agent cyclophosphamide and is implicated in off-target 
effects, including to bladder hemorrhagic cystitis and cyclophosphamide-induced cardiotoxicity, 
both of which have led to serious secondary iatrogenic injury during and following chemotherapy. 
At low concentrations acrolein inhibits cell proliferation without inducing apoptosis, while at high 
concentrations may result in secondary apoptosis promotion. This investigation assessed the role 
of the enzyme poly (ADP-ribose) polymerase (PARP) in acrolein induced toxicity using the 
established toxicological H9c2 (2-1) cardiomyoblast in vitro model. H9c2 (2-1) cells were plated 
in 24-well plates at 75,000 cells per well three days prior to testing, followed by acrolein dosing 
at concentrations between 10 µM and 1000µM for either 30 or 55 minutes. PARP activity was 
quantitatively measured in total cell lysates using a biotin-avidin-conjugated horseradish 
peroxidase-TMB reporter system in a 96-well microplate formate. The lowest effective dose of 
toxicity at 30 minute dosing was found at 25 μM (PARP Activity 1.65-fold control) which returned 
to baseline at 100 μM; concentrations at or above 250 μM results in significant PARP activity 
reductions (≤ 0.46-fold control). Biomarkers were further characterized for cytotoxicity (AST 
presence), and viability (MTT reduction) in order to facilitate mechanistic characterization of 
PARP-mediated acrolein cardiotoxicity. Investigation of a PARP inhibitor was assessed to explore 
the intervention for acrolein induced cardiac tissue damage. 
1 
 
 
 
 
CHAPTER ONE: 
INTRODUCTION 
Acrolein 
 Acrolein (C3H4O, CAS No. 107-02-8) is a α,β-unsaturated aldehyde which is extremely 
electrophilic. According to the American Cancer Society 1:8 or 12% of women in America will 
develop breast cancer within their lifetime, excluding skin cancers breast cancer is the most 
common cancer of women in America (American Cancer Society, 2016). Cyclophosphamide as 
an antitumor prodrug is commonly used for treatment of broad spectrum human cancers. 
Routinely, it is most prescribed for treatment of breast cancers, ovarian cancers and lymphomas 
(Chan, 1984).  Cyclophosphamide is itself inactive, thus requiring an enzyme mediated 
bioactivation to induce cytostatic activity. As a prodrug cyclophosphamide is categorized as an 
alkyling agent, once it undergoes activation it forms aldophosphamide. The active metabolite of 
cyclophosphamide is phosphoramide mustard and the toxic metabolite is acrolein both are 
produced during biotransformation of aldophosphamide (Conklin et al., 2015).  Phosphoramide 
mustard, uses ion intermediates to help with inhibition of DNA replication and activation of 
apoptotic pathways.  This is accomplished by phosphoramide mustard creating DNA crosslinks 
(interstrand/intrastrand) at the 7-nitrogen atom which initiates cellular death pathways.  As a bi-
product of the transformation of aldophosphamide into phosphoramide mustard acrolein is also 
formed (de Jonge, Huitema, Rodenhuis, & Beijnen, 2005). Like many other metabolites derived 
through phase II xenobiotic metabolism, acrolein is far more toxic than its derivative 
cyclophosphamide. Acrolein as an electrophilic α, β-unsaturated aldehyde, is implicated in off-
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target effects including bladder hemorrhagic cystitis and cardiotoxicity. Due to its electrophilic 
nature acrolein is highly capable of reacting rapidly at several cellular sites, coupled with its 
cellular irritation effects , its presence proves to be a  highly problematic and is attributed with 
being the main source cyclophosphamide treatment toxicity (Kehrer & Biswal, 2000).  At low 
concentrations acrolein inhibits cell proliferation without inducing apoptosis, while at high 
concentrations its presence may result in secondary apoptosis promotion (Mohammad et al., 2012).   
 Select chemotherapeutic drugs are associated with several cardiotoxic side effects. 
Complications transverse a wide spectrum but more common side effects of chemotherapeutic 
treatment include pericarditis, isolated arrhythmias, myocarditis, cardiomyopathy, and cardiac 
failure. Risk factors associated with individuals developing cardiotoxicity pose treatment of a 
chemotherapeutic drug is directly associated with the cumulative dose per treatment.  Alkylating 
agents contradict anthracycline agents which follow a dose-response dependent relationship or 
lifetime dose. Incidences of disease are highly dependent upon a dose-concentration per 
administration (Dadfarmay, Berkowitz, & Kim, 2012). High dose concentrations of 
cyclophosphamide therapy can result in cardiac toxicity. High dose concentrations are defined as 
144-270 mg/kg, administration at these level can lead to death which is endorsed by heart failure 
(Chan, 1984).  Doses attributed with a 25% incidence of cardiotoxicity are ~ 240mg/kg, although 
cardiac toxicity has been seen in dosage as low as 144 mg/kg.  Cyclophosphamides clinical 
manifestations of cardiotoxicity include arrhythmias, cardiac enzymes elevation, congestive heart 
failure, electrocardiographic voltages dampening, pericarditis and transient cardiomegaly 
(Langford, 1997). Current data on cardiotoxicity of cyclophosphamide shows a need for 
developing intervention methods to help mitigate the damages of acrolein induced toxicity. 
Administration of cyclophosphamide at high treatment levels is associated with acute-cardio-
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toxicity.  This associated toxicity has shown that GSH plays an integral role in protection against 
cardio-toxicity, acrolein prompted glutathione depletion is tied to cyclophosphamide associated 
cardiotoxicity (de Jonge et al., 2005).   
 
H9c2(2-1) Model 
 
 A century has passed since Ross Harrison completed the first successful culturing of cells, 
leading him to be known as the father of cell culture. Although cell culturing techniques began in 
the 20th century, techniques continue to evolve and advance today (Rodriquez-Hernandez, 2014). 
The establishment of the H9c2 line in the 1970’s has proven that this cell model is useful for 
utilization in toxicological testing.  The H9c2 (2-1) is a myoblast sub-clone derived from 
embryonic BDIX rat heart tissue the original clonal line developed by B. Brandt and B. Kimes 
(Hescheler et al., 1991).  The H9c2 (2-1) cell line is largely valuable when compared to primary 
cultures or whole tissues due to its ability to remain more homogenous phenotypically, this 
stability transcends electrophysiology, morphology and biochemistry properties. These 
characteristics help make the H9c2 (2-1) cell line an excellent model choice when studying cellular 
development or cellular death.  Studying culturing conditions has shown the H9c2 (2-1)  cell line 
successively propagates for months without undergoing any characteristic changes (Kimes & 
Brandt, 1976). The H9c2 (2-1) cell line is proven in-vitro model for studying cardiac and skeletal 
muscle. Additionally it is invaluable model due to its ability to remain a myoblast when serum 
concentration are supported, providing multiple generations for testing helping to reduce the need 
for controlling  batch variation.  The ability to test H9c2 cells within a reasonable propagation 
range help to ensure treatment is performed on cells similar in terms viability, morphology, and 
biological properties. The H9c2 (2-1) cell line is also valuable due to its ability to differentiate 
when serum concentration are reduced allowing the newly differentiated cells to contain several 
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elements of cardiac cells. These similarities allow differentiated cells to be used for testing 
cardiovascular diseases, including the assessment of preventative measures and mechanistic 
pathways (Sardao, Oliveira, Holy, Oliveira, & Wallace, 2007). The in-vitro model for H9c2 cells 
is currently used to evaluate and manipulate signaling pathways, cellular mechanism, and 
enzymatic signaling involved in cardiotoxicity. More specifically the use of H9c2 (2-1) cells lines 
has helped to distinguish drug-induced cardiotoxicity characteristics along with possible 
intervention methods (Aboutabl & El-Kadi, 2007). In recent studies the H9c2 model has confirmed 
that cultured primary cardiomyocytes have the ability to be used for studying the hearts metabolic 
capacity. Stemming from these results the H9c2 cell line was also assessed for its ability to be used 
as an in-vitro model for heart enzymes associated with drug metabolism. The authors were able to 
show that expression of CYP1A1 and 1B1 occurs in H9c2 cell lines, additionally the expression 
can be manipulated through the addition of an inducer (Zordoky & El-Kadi, 2007).  Studies have 
also shown that cellular viability of the H9c2 cell line can be measured by using 3-(4,5-
Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) levels (Aboutabl & El-Kadi, 
2007).  
 
 Poly(ADP-Ribose) Polymerase 
 
 Current knowledge of enzyme family of Poly(ADP-Ribose) Polymerase (PARPs) has led 
to the discovery of 18 known members, each varies based on cellular function, molecular weight, 
composition, location, but all have conservation that is supported by ADP-ribosylating catalytic 
domain. Poly(ADP-Ribose) polymerase is classified as a chromatin-associated nuclear enzyme, 
its activation occurs due to DNA damage. DNA repair is an extremely energy-dependent process 
and apoptosis is an extremely energy-dependent process. As DNA damage is assessed and 
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repaired, cellular energy will be depleted based on the extent of the damage.  An integral part of 
the process is carried out by the DNA repair enzyme poly(ADP-Ribose) Polymerase.  PARP 
activation occurs when a cell undergoes DNA damage, typically in the form of strand breaks (Jin 
& El-Deiry, 2005). Through the attachment of poly(ADP-Ribose) units the cell can modify nuclear 
proteins. Activated PARP leads to poly(ADP-Ribosyl)ation of many cellular proteins (histones, 
DNA, topoisomerases I & II, PARP) protein activation in turn leads to activation of different 
pathways (Kaplan, O'Connor, Hake, & Zingarelli, 2005). Poly(ADP-Ribose) polymerase as an 
enzyme works by detecting DNA strand breakage. After detection of DNA damage PARP 
catalyzes ADP-ribose transfer from co-enzyme NAD+ to help bind DNA. (Dantzer et al., 1999) 
Cellular damage can occur directly though genotoxic agents (oxidation, ionization, alkylation) or 
as an indirect process post-enzymatic incision. Cellular viability is highly dependent upon the 
energy depletion as cells undergo repair processes.  
 PARP-1 which is the most abundant isoform of PARP in the human body is found in the 
nucleus of the cell, its main function is the detections of single-stranded DNA breaks (SSB). 
PARP-1 also plays an integral role in cell death, over-activation of PARP-1 leads to significant 
genomic stress thus causing extreme cellular inflammation due to ATP & NAD depletion 
(Rouleau, Patel, Hendzel, Kaufmann, & Poirier, 2010). These energy depletions will lead the cell 
to undergo cellular death through necrosis. Previous studies have confirmed a direct inverse 
relationship between NAD+   and PARP. Decrement of NAD+ effect cellular glycolysis including 
the Krebs cycle and the redox state of cells  (Bouchard, Rouleau, & Poirier, 2003).  PARP-1 is 
also attributed to causing cellular death through apoptosis, this can occur through several processes 
including caspase-dependent apoptosis, factor-mediated, and caspase-independent apoptosis. 
Additionally PARP-1 interaction with a down-stream cell death effector (PAR polymer) leads to 
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parthanatos cell death. PARPs role in all forms of cellular death including programmed, necrosis 
and apoptosis is dependent upon the amount of  PARP activation, pathway selection, cellular 
metabolic status, and intervention factors (Rosado, Bennici, Novelli, & Pioli, 2013). The 
difference between apoptosis and necrosis is determined by biochemical and morphological 
features.  Necrosis is defined as the occurrence of cell death as a consequence of acute damage 
due to disease or injury which lead to an inflammatory response. Apoptosis is characterized as a 
programmed cell death (Hong, Dawson, & Dawson, 2004). Early phase apoptosis is triggered 
when transient PARP activation occurs (pre-caspase-mediated-cleavage) and is controlled by the 
integral relationship between PARP and poly(ADP-ribosyl)ation. PARP as an important 
determinant of programmed cell death is responsible for inhibiting or selection apoptosis or 
necrosis pathways. During apoptosis PARP cleavage occurs parallel to caspase activation. PARP 
cleavage is believed to be responsible for the depletion of energy needed in late-stage apoptosis 
(Herceg & Wang, 2001). Within apoptosis and necrosis there are well defined cell death processes 
which are unique to injury induction and cell type. PARP-1 is responsible for PARP-1 mediated 
apoptosis-inducing factor (AIF). This pathway is linked to ischemic injury and excitotoxic cell 
death. Hypothesis for PARP-1 mediated cell death involves the rapid depletion of cellular ATP 
and NAD+ due to the over activation of PARP. The reduction of these energy sources affects 
cellular metabolism and lead to apoptosis. Cell death is heavily dependent upon mitochondria 
(cellular powerhouse) and nucleus (DNA) health. When either of these organelles is damaged 
beyond repair signaling determines cellular death pathways, which are dependent upon PARP 
(Hong et al., 2004). 
 Clinical trials are evaluating PARP-1 inhibitors’ ability to be used as a therapeutic agents, 
primarily for tertiary care of cancers, inflammatory and autoimmune diseases.  The use of an 
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inhibitor is proving beneficial due the role of PARP in DNA damage detection and base excision 
repair. PARP inhibitors have been shown through several experimental models to have protective 
effects against acute and chronic inflammatory diseases  (Rosado et al., 2013). In-vitro studies 
have shown that use of a PARP inhibitor helps render a cell resistant to death by certain inducers, 
one of which including alkylating agents. These same studies demonstrated that PARP inhibition 
has shown protective for skeletal muscular and cardiac tissues when ischemia reperfusion was the 
attributed cause of damage (Herceg & Wang, 2001). PARP inhibitors are chemical agents that are 
designed to compete at the enzyme activation cites with NAD+.  When a PARP inhibitor is 
introduced it acts as a competitive agent against PARP, preventing the repair of DNA damage 
(Rouleau et al., 2010). 
 
DIQ 1,5-dihydroxyisoquinoline 
 DIQ 1,5-dihydroxyisoquinoline (C9H7NO2  CAS No. 5154-02-9) is a potent PARP 
inhibitor that is activated by nitric oxide. Previous studies have shown 1,5-dihydroxyisoquinoline 
(DIQ) to have a high selectivity for PARP inhibition, pharmacological studies have shown this 
inhibition helps with the reduction of myocardial damage and increases the viability of cells by 
inhibiting apoptosis. In-vivo studies of rats which were treated with DIQ showed that PARP-1 
inhibition resulted in reduction of infarct size and significant cardio protection, especially in 
reperfusion linked injury.  DIQ has been shown to inhibit PARP –induced inflammatory responses 
which lead to cells undergoing necrosis (Kaplan et al., 2005). PARP inhibitors have also shown 
that following a sublethal-treatment of alkylating agents have the ability to suppress certain 
signaling pathways driving the damaged cell towards apoptosis instead of necrosis. This is further 
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characterized through PARP cleavage and PARPs inactivation by caspase-3, both of which are 
proven markers of that the damaged cell has undergone apoptosis (Dantzer et al., 1999). 
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CHAPTER TWO: 
 
METHODS 
 
Cell Culture 
 H9c2(2-1) Rat Embryonic Myoblasts cell line were obtained from the American Type 
Culture Collect (ATCC) (Manassa, VA) and cultured under humidified conditions, with a 5% CO2 
at 37°C.  Cellular medium consisted of Debulcco’s Modified Essential Medium (DMEM) 
(Corning, Manassa, VA) containing 1% - 100U/mL and100mg/mL penicillin and streptomycin, 
10% fetal bovine serum (ATCC), and 1% L-glutamine. (Zordoky & El-Kadi, 2007) Every two-
three days medium was changed to provide cells with fresh nutrients. Subdivision of cells occurred 
when plates reached 80-90% confluence to maintain cells exponential growth. Subdivision was 
performed by aspirating then washing the plates with phosphate buffered saline (PBS) without 
calcium or magnesium (Corning) followed with a light trypsinization [0.1% Trypsin EDTA in PBS 
(Corning)] incubated at 37°C for 5 minutes. The trypsinization reaction was stopped through 
adding a 1:1 of DMEM, cells were then separated through centrifugation at 250 x g for 4 minutes. 
Post-centrifugation, supernatant was aspirated allowing resuspension of cells with fresh DMEM. 
Cells were either plated in tissue-culture treated plates for testing or re-plated to continue 
propagation. The H9c2(2-1) cells used for experimentation fell within the 5th -12th passage to help 
ensure stability, consistency and reduce the likelihood of genotype-variation.  Exposure periods 
would only occur after allowing cells sufficient time to reattach to plates, time periods were 
determined by analysis performed.  
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Treatment  
 H9c2(2-1) cells were plated into tissue culture-treated microplates at 1,000 cells per well 
(96-well) or 75,000 cells per well (24-well) 72 hours prior to MTT or PARP activity assessment, 
respectively. For AST cells were plated at 10,000 cells per well into 96-well plates 48 hours prior 
to activity assessment. To prepare for biological marker experimentation, cell were aspirated, 
washed, and underwent a 30 minute pre-incubation with either a vehicle or PARP inhibitor. PARP 
inhibitor groups received 100 µM DIQ 30 minutes prior to dosing, and paired with vehicle-only 
(DMSO) controls. Replacement medium contained either a 0.3% vehicle (DMSO) or 0.3% PARP 
inhibitor DIQ. Cells were then underwent a 30 minute exposure period with or without the PARP 
inhibitor DIQ with acrolein at concentrations varying between 10 µM and 1000 µM; controls 
received medium containing hydroquinone at the same dilution as the 1000 µM acrolein group. 
For PARP assay experimentation cells were not treated with PARP inhibitor, cells were treated 
with acrolein only at two time points, 30 or 55 minutes respectively. For MTT and AST cells 
underwent a 30 minute pre-incubation with either a vehicle or PARP inhibitor, cells were then 
underwent a 30 minute acrolein exposure followed by a wash out period.  MTT and AST test were 
given a 100 mM DIQ PARP inhibitor and then groups were treated with acrolein at concentrations 
varying between 10 µM and 1000 µM. 
 
Poly(ADP-Ribose) Polymerase Activity 
For PARP activity assessment, cells were treated with acrolein for 30 or 55 minutes, lysed 
in a PARP stabilizing buffer, and protein quantified via the Bradford method. A 10X stock solution 
which was diluted down to 1X PARP stabilizing buffer, was iced, and mixed with samples on ice. 
Each 24-well plate was iced and then received 75 µl of cold 1X PARP buffer per well. PARP lysis 
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buffer is made fresh each treatment day by diluting down from a 10X stock PARP buffer solution.  
The 10X PARP buffer solution consisted of tris base (500 mM), magnesium chloride 
MgCl2·6H2O (20 mM), triton x-100 (1% or 0.01), bovine serum albumin (1000 μg/mL), 
hydrochloric acid HCl (1.78 M pH to 8.00), and autoclaved U.P. H2O to bring to final volume. 
For PARP analysis protein quantification was used to set all samples to the required 8 µg of 
protein. The Bradford Reagent was prepared using Marion M. Bradford’s recipe of dissolving 100 
mg of Coomassie Blue into 50 ml of 95% ethanol solution, additionally 100 ml of 85% phosphoric 
acid solution was added. The final solution was then diluted down into a 1 liter total volume 
solution. The Bradford Reagent final concentrations are 0.01% Coomassie Blue (w/v), 8.5% 
phosphoric acid (w/v) and 4.7% ethanol (w/v). (Bradford, 1976). This solution then underwent 
double filtration before being used for protein quantification of PARP lysis samples.  Standards 
used to build the curve for protein quantification included 2,000 / 1,000 /500, 250, 125, 65.5, 31.25, 
15.625 and 0. These standards were built using the bovine serum albumin (BSA) albumin standard 
ampules provided in the BCA protein assay kit (Thermo Fisher).  Standards and samples were run 
in duplicates and read via UV-VIS spectrophotometer at 595 nm. Raw data for each duplicate was 
averaged, blanked and quantified to determine the dilution concentration to standardize all samples 
to 8 µg protein for loading in the in house PARP assay.  
To evaluate Poly(ADP-Ribose) Polymerase activity and in house PARP Assay was used 
which uses a quantitative colorimetric endpoint.  The protocol for this assay spans across a three 
day period. On the first day a high binding 96-well plate (Fisher -Perkin Eelmer) is prepared to 
plate histones. A histone plating solution is made and then 50 μL of histone plating solution is 
added to each well. The histone plating solution consists of 90 mM sodium carbonateNa2CO3, 10 
mM sodium bicarbonateNaHCO3, histone solution 0.1 mg/ml and autoclaved U.P. H2O (to bring 
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to final volume). After each well receives the plating solution the plate is sealed with parafilm and 
incubated overnight at 4°C to allow the histones to adhere to the plate.  The second day involves 
blocking the plate. The plate undergoes a series of washes with each wash including a 5 minute 
incubation period at 23°C. The first wash solution consists of Phosphate Buffered Saline 
supplemented with 0.05% Tween-20 (PBS-T), 200 µl/well the wash is repeated twice. The second 
wash solution consists of Phosphate Buffered Saline (PBS), 200 µl/well also repeated twice.  
Following the final wash a 3% BSA blocking buffer is added to each well followed by an overnight 
incubation at 4°C.  The third day of this assay involves the detection of PARP. 
 PARP activity was assessed using 8 µg of lysate, based on the results of the Bradford 
protein quantification.  Preparation of samples included dilution in 1X PARP buffer prepared on 
ice, PARP HAS standards for determining calibration curve are also diluted using 1X PARP buffer 
prepared on ice. A working PARP cocktail solution is prepared immediately prior to use. This 
solution is diluted down from a 10X PARP cocktail stored in -20°C into a 1:10 solution using 
autoclaved U.P. H2O.  The 10X PARP cocktail contains NAD
+ and Biotinylated-NAD; the sum of 
both NAD+/B in the 1X working reagent is 3 mM. Immediately prior to use a 1:10 of Sheared 
Herring Sperm DNA is added into 1X PARP cocktail. Once all cocktails and samples have been 
prepared the plate is removed from the 4°C refrigerator and undergoes two wash cycles of 200 μL 
of PBS-T and PBS repeating the wash regime from day 2.  Post washing 25 μL of PARP HSA 
standards and samples were added in duplicates to their respective wells, this is followed by the 
addition of 25 μL of 1X PARP cocktail. Mixing occurs via tapping followed by a 60 minute 
incubation at 21°C. Following PARP cocktail incubation plates are washed 3 times consecutively 
each with PBS-T and PBS. Post washing 50 μL of 1:60,000 Streptavidin-HRP is added, mixed, 
and then incubated at 21°C for 60 minutes. Following Streptavidin-HRP incubation plates are 
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washed 3 times consecutively each with PBS-T and PBS. Post washing 50 μL 3,3',5,5'-
Tetramethylbenzidine (TMB) is added in the dark to each well, incubation occurs for 30 minutes 
at 21°C.  Wells will turn bright blue based on PARP activity. Post incubation 65 μL of 0.2M 
hydrochloric acid is used to stop the reaction. Plates are mixed and then stand for 10 minutes before 
being read via UV-VIS spectrophotometer at 412 nm.  
Cytotoxicity Assessment 
 
MTT, 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide  
 
 For MTT activity assessment, cells were plated at 1,000 cells per well (96-well), pre 
incubated with DMSO or DIQ and then treated with acrolein for 30 minutes.  Standards were ran 
in triplicates, while samples were ran in 6 replicates. Standard curve was built by plating at 2,000/ 
1,500/ 1,000/ 800, 600,400,200 and a DMEM blank.  Samples were aspirated, washed, and 
replaced with 50 μL DMEM containing 0.3% DIQ or 0.3% DMSO for a 30 minute pre-incubation. 
Post incubation samples were treated with 50 μL DMEM containing acrolein at concentrations 
varying between 10 µM and 1000 µM; controls received medium containing hydroquinone at the 
same dilution as the 1000 µM acrolein group. Following treatment cells were aspirated, washed, 
and replaced with 50 μL fresh DMEM followed by a 4 hour wash-out period. Thereafter, cells 
were incubated for 2 hours with MTT at a 1:10 dilution at standard culturing conditions. MTT-
supplemented medium was then replaced with 100 μL DMSO in order to solubilize the reduced 
formazan in preparation for UV-VIS measurement at 570 nm. For analysis standards were blanked 
against DMEM, samples were blanked against DMEM containing 0.3% hydroquinone solution. 
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AST, Aspartate Aminotransferase 
 
For AST cells were plated at 10,000 cells per well (96-well). Samples were run in 
triplicates, they were aspirated, washed, and replaced with 50 μL DMEM containing 0.3% DIQ or 
0.3% DMSO for a 30 minute pre-incubation. Post incubation samples were treated with 50 μL 
DMEM containing acrolein at concentrations varying between 10 µM and 1000 µM; controls 
received medium containing hydroquinone at the same dilution as the 1000 µM acrolein group. 
Following treatment cells were aspirated, washed, and replaced with 35 μL fresh DMEM followed 
by a 6 hour wash-out period. Thereafter, 10 μL medium of sample was re-plated in duplicates into 
a new 96-well plate.  Each well plate contained standards, blanks, and AST calibrator also plated 
at 10 μL in duplicates. The standard curve was derived using Oxaloacetate diluted in PBS to 10 
μM then serially diluted to 5μM, 2.5mM 1μM, 0.5μM, 0.25μM, 0.125μM.  Once all standards, 
samples, blanks and calibrator were plated 50 μL AST Substrate was added every 10 seconds using 
a multichannel pipette. Plates were then incubated for 10 minutes at 37°C.  Following substrate 
incubation 50 μL AST color developer was added every 10 seconds using a multichannel pipette. 
Plates were again incubated for 10 minutes at 37°C. Finally 100 μL 0.2M HCL was added using a 
multichannel pipette. Plates were then incubated for 10 minutes at 21°C. Thereafter, samples were 
ran in UV-VIS measurement at 530 nm. For analysis standards were blanked against PBS while 
samples were blanked against DMEM. Quantified results were converted using 78.8 IU/L to 
standardize AST signal.  
 
Spectrophotometric Quantification 
 
Assays which required assessment of colorimetric endpoints (AST, MTT, and PARP) were 
quantified using the µQuant Spectrophotometer (BioTek, Winooski, VT) coupled with the KC-
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Junior Analytical software (BioTek). Each colorimetric endpoint that was assessed was set at the 
wavelength suggested by the manufacturer. Assays were read via UV-VIS spectrophotometer at: 
PARP 412 nm, MTT 570 nm, and AST 530 nm. 
 
Statistical Analysis 
 
Statistical analysis was performed utilizing Microsoft Excel. Standards were averaged, 
blanked and quantified to be used for analyzing samples. Samples were averaged, blanked, and 
used standards quadratic equation to be quantified. Additional analysis was performed to derive 
fold and standard deviation values. Fold averages and fold deviations were further analyzed by 
aggregating all of the test to determine each treatment group’s average, standard deviation, 95% 
confidence interval and t-test. Aggregated data was processed using SPSS predictive analytics 
software to identify and eliminate outliers. Outliers were classified as falling 3 standard deviations 
below/above the standard mean. Statistical significance was determined when the probability of 
reaching the measured statistic fell at or below 5.0 % (p ≤ 0.05).  
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CHAPTER THREE: 
 
RESULTS 
Summary: Cytotoxicity  
 Looking at the H9c2 (2-1) cell line as an in-vitro model is beneficial for analyzing the role 
that Poly(ADP-Ribose) Polymerase and PARP inhibitors play in acrolein induced-cytotoxicity.  In 
assessing poly(ADP-ribose) polymerase activity post treatment across two time points it was 
apparent that a treatment-dependent relationship was demonstrated when assessing PARP activity 
against acrolein concentration. For this analysis two bio-markers of cytotoxicity were utilized to 
interpret the degree of cellular death post treatment. First cellular viability was assed using the 
mitochondrial succinate dehydrogenase-dependent MTT reduction assay.  Then aspartate 
aminotransferase (AST) assay was used to measure colorimetric analysis in units/liter (U/L) the 
reaction between each lysates’ enzyme and substrate.  Aspartate aminotransferase was able to 
provide evidence of membrane degradation, cellular damage and ultimately viability offering a 
comparison between treatment and vehicle medium.  While signal strength was week and fell 
below detection limits in lower treatment groups the AST assay still represented a relevant toxic 
endpoint.  Both of these assays demonstrated DIQ’s ability to increase cellular viability, although 
statistical significance was only reached in two treatment groups.  
 
Poly(ADP-Ribose) Polymerase Activity 
 To prepare for PARP analysis 75,000 cells were plated into 24-well plate to allow for a 30 
minute or 55 minute time exposure to acrolein treatment groups varying in concentrations of 10 
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µM-1000µM. Post exposure, cells were washed using PBS and lysed using a prepared ice-cold 
lysis buffer which was supplemented with Triton-X-100.  Lysis of cells occurred over ice and 
protein lysates were collected in triplicates, with one being used for quantification via Bradford 
method. For the PARP assay the amount of purified cellular protein required was standardized to 
8 micrograms per sample.  The standard curve was calibrated and quantified for further analysis 
of PARP activity in samples.  Samples duplicates were first averaged, blanked and then quantified 
against the quadratic equation generated by the standards. This created an x-axis of PARP activity 
in 8 µg against the y-axis of treatment groups. The lowest effective concentration of toxicity at 30 
minute exposure was found at 25 μM (PARP Activity 1.65-fold control) [Figure 1.] which returned 
to baseline at 100 μM; concentrations at or above 250 μM results in significant PARP activity 
reductions (≤ 0.46-fold control). This evidence suggests that acrolein induced cardiotoxicity may 
be modulated through PARP inhibition. . There was no lowest effective concentration of toxicity 
at 55 minute exposure. [Figure 2.]  All concentrations when compared to control results had 
significant PARP activity reductions (≤ 0.98-fold control). This evidence suggests that acrolein 
induced cardiotoxicity may be modulated through PARP inhibition, but against longer exposure 
periods samples folds will significantly reduce linearly with time.  [Figure 3.]   
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Figure 1: Poly(ADP-Ribose) Activity 30 Minutes:  PARP Activity (fold-control) assessed 30 minutes after exposure 
with acrolein. Two positive statistical significant differences were observed when compared to control in the 25 μM 
& 50 μM treatment groups. All treatment groups ≥250 μM reached negative statistical significance when compared 
to fold control.  
 
 
 
Figure 2: Poly(ADP-Ribose) Activity 55 Minutes:  PARP Activity (fold-control) assessed 55 minutes after exposure 
with acrolein. No treatment groups reached statistical significant All treatment groups ≥10 μM had PARP activity that 
fell below fold control. 
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Figure 3: Poly(ADP-Ribose) Activity Comparison: PARP Activity (fold-control) assessed at 30 & 55 minutes after 
exposure with acrolein. Only treatment groups at the 30 minute time point reached positive/negative statistical 
significance. At either time point acrolein treatment groups ≥250 μM had PARP activity that fell below fold control. 
 
 
Toxicological Endpoints 
MTT, 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide  
To prepare for MTT analysis 1,000 cells were plated into 96-well plate to allow for a 30 
minute time exposure to acrolein treatment groups varying in concentrations of 10 µM-1000µM. 
Post exposure, cells were washed using PBS, underwent a 4 hour wash out, and then had medium 
replaced with 1:10 dilution of formazin for a 2 hour incubation. Cells were then aspirated and 
formazin crystals were re- solubilized using DMSO. The MTT analysis was preformed through a 
colorimetric assay which was used to determine the amount of cellular enzyme activity present 
based on the amount tetrazolium dye reduced. The reduction produces an insoluble formazan 
which is re-solubilized to produce a purple color. Based on the color gradient read via UV-VIS 
spectrophotometer cytotoxicity can be assessed (Riss et al., 2004).  Standard curves were built 
using cell plating ranging from 200-2,000 cells, readings were calibrated then quantified for further 
analysis of MTT activity in samples.  Treatment groups duplicates were averaged, blanked and 
then quantified against the standards. In MTT the concentrations of toxicity for acrolein which the 
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DIQ treatment had the greatest protection was found at 25 μM & 50 μM when comparing to the 
vehicle in the MTT analysis. (MTT Activity 0.05 & 0.003 T-Test) [Figure 4.]  At ≥250 μM DIQ 
provided no significant protections (MTT Activity 0.119, 0.527, 0.463 T-Test).  At ≤100 μM DIQ 
protection was limited (MTT Activity 0.065 T-Test). Statistical analysis was further assessed to 
determine if any outliers were skewing data results. Treatment groups’ data were assessed by either 
vehicle or DIQ. In vehicle treatment groups (DMSO) two outliers were assessed. [Figure 5.]  After 
their removal standard deviations in the 100 μM & 1000 μM reduced. (100 μM 0.37 -> 0.21 & 
1000 μM 0.05 -> 0.03) In PARP inhibitor treatment groups (DIQ) two outliers were assessed. 
[Figure 6.]  After their removal standard deviations in the 25 μM & 50 μM decreased. (25 μM 0.28 
-> 0.16 & 50 μM 0.25 -> 0.12) 
 
 
Figure 4: MTT Activity: MTT Activity (fold-control) assessed 30 minutes after exposure with acrolein. Two positive 
statistically significant differences were observed when compared to control in the 25 μM & 50 μM treatment groups. 
All treatment groups ≥250 μM showed some protections but none reached statistical significance when compared to 
fold control. At ≤100 μM DIQ protection was limited 
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Figure 5: Vehicle Box Plot MTT: Outliers were processed using SPSS predictive analytics software. Circles noted 
in reader results denote outliers. Outliers were processed using aggregated fold averages for all trials. °37 Fell under 
Trial 5 -100 μM treatment group. The fold value .53 fell more than 3 standard deviations above the average after its 
removal from the data set so its value was thrown out. . °64 Fell under Trial 8 -1000 μM treatment group. The fold 
value .14 fell more than 3 standard deviations above the average after its removal from the data set so its value was 
thrown out.  
 
 
Figure 6: DIQ Box Plot MTT: Outliers were processed using SPSS predictive analytics software. Circles noted in 
reader results denote outliers. Outliers were processed using aggregated fold averages for all trials. °20 Fell under 
Trial 4 -25 μM treatment group. The fold value .33 fell more than 3 standard deviations below the average after its 
removal from the data set so its value was thrown out. . °28 Fell under Trial 4 -50 μM treatment group. The fold value 
.22 fell more than 3 standard deviations below the average after its removal from the data set so its value was thrown 
out. 
 
AST, Aspartate Aminotransferase 
To prepare for AST analysis 10,000 cells were plated into 96-well plate treated at groups varying 
in concentrations of 10 µM-1000µM for a 30 minute exposure period. Post exposure, cells were 
washed using PBS, underwent a 6 hour wash out with fresh medium, and then had 10 µl of lysate 
medium collected and replated in duplicate into a new 96-well plate. In this assay glutamate 
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oxaloacetate transaminase (GOT) is reduced using tetrazolium enzymatic reaction with oxalacetic 
acid yielding a red compound to be read and standardized against a calibrator. Standard curves 
were built using Oxaloacetate ranging from 10 μM -0.125μM. Samples underwent substrate, color 
developer, and HCL incubations prior to being read via UV-VIS spectrophotometer. For AST the 
only treatment groups which were read above the detection limits were ≥ 250 μM.  No AST 
treatment concentrations reached Significance due to control Variability, at 250 μM & 500 μM 
DIQ protection was limited (AST Activity 0.09 & 0.26 T-Test). In 1000 μM DIQ treatment groups 
an adverse effect was seen in vehicle treatment groups having higher viability. (AST Activity 
0.175 t-test) [Figure 7.] Further statistical analysis was performed using SPSS to determine if any 
outliers existed for trials. Data was aggregated by either vehicle or DIQ. Statistical analysis was 
further assessed to determine if any outliers were skewing data results. Treatment groups’ data 
were assessed by either vehicle or DIQ. In vehicle treatment groups (DMSO) no outliers were 
present. [Figure 8.] In PARP inhibitor treatment groups (DIQ) no outliers were present. [Figure 
9.] 
 
Figure 7: Aspartate Aminotransferase Activity AST Activity (fold-control) assessed 30 minutes after exposure 
with acrolein. No treatment groups reached statistical significance due to control variability.  
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Figure 8: Vehicle Box Plot AST: Outliers were processed using SPSS predictive analytics software. Circles noted in 
reader results denote outliers. No outliers were detected. 
 
 
 
 
Figure 9: DIQ Box Plot AST: Outliers were processed using SPSS predictive analytics software. Circles noted in 
reader results denote outliers. No outliers were detected.  
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CHAPTER FOUR: 
 
DISCUSSION 
This investigation explored the role of Acrolein-induced Toxicity using the H9c2 model, 
and what role PARP inhibitors play in helping reduce cytotoxicity.  Chemotherapy induced cardio-
toxicity is a well-documented side effect of undergoing prodrug treatments. Cardiotoxicity due to 
molecular mechanisms of oxidative stress can lead to apoptosis due to cytotoxicity  (Angsutararux, 
Luanpitpong, & Issaragrisil, 2015). Cytotoxic potentials of cyclophosphamide and acrolein are 
being assessed at in-vivo and in-vitro levels. Understanding the mechanistic differences between 
administrations of toxicants of cellular vs. whole systems is important for furthering research into 
preventative measures. Cyclophosphamides toxicity is greatest after it has undergone microsomal 
oxidation generating acrolein, the cytotoxic aldehyde (Sladek, 1973).  Cyclophosphamide 
activation forms 4-hydroxycyclophosphamide, which is readily diffused within cells and is not a 
cytotoxic compound. It does spontaneously decompose due to being incredibly instable leading to 
the formation of phosphoramide mustard and acrolein. Acrolein is highly reactive aldehyde, 
making it extremely cytotoxic. Previous studies have contributed ATP reduction as a major 
contributor to acrolein-mediated necrosis. Possible explanations for the depletion of ATP include 
the over-activation of PARP, thus leading to reduced ATP because of the energy taking process of 
PARP’s substrate regeneration (Kern & Kehrer, 2002). Another possibility for the enhanced 
cytotoxicity of acrolein is glutathione depletion at the cellular level due to conjugation (de Jonge 
et al., 2005).  Previous studies have supported that mitochondria lack glutathione biosynthesis 
enzymes, thus GSH must be transported from the cytosol into the mitochondria by using a high 
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affinity transporter. This means that acrolein conjugation leads to the depletion of glutathione not 
GSH oxidation (Arumugam, Thanislass, Ragunath, Niranjali Devaraj, & Devaraj, 1999).  Previous 
studies have also linked the unsaturated nature of acrolein as the cause for the stark depletion of 
cytosolic glutathione, in-vivo rat studies have shown an unchanged content of GSSG in acrolein-
treated rats, and thus GSH oxidation pathways went unused (Arumugam et al., 1999). Potential 
biomarkers have been identified and could be used to assess the amount of acrolein conjugation 
occurring in individuals’ undergoing chemotherapy treatments of cyclophosphamide. Conjugation 
of glutathione with acrolein produces 3-hydroxypropylmercapturic acid. Previous studies have 
found that 3-hydroxypropylmercapturic acid is detectable through urinalysis of individuals and 
rats treated with cyclophosphamide (Faroon et al., 2008). The ability of 3-
hydroxypropylmercapturic acid production as a measurement tool for elucidating the amount of 
acrolein bi-product produced from chemotherapy treatments should be further assessed.  
PARP-1 activation is responsible for mediation of cell death, through signaling 
downstream apoptotic effectors. PARP-1 activation has been proven to mediate pathways for cells 
which underwent damage induced through reperfusion injury, reactive oxygen species injury, 
inflammatory injury, and ischemia injury (Yu et al., 2002). PARP inhibitors are undergoing 
clinical development to be used as a therapeutic agent. Currently a two-pronged approach is being 
utilized. First is the targeting of cells that have a genetic predisposition toward death when PARP 
activity is inhibited. The second therapeutic approach is looking at the benefits of PARP-inhibition 
to prevent DNA repair, thus forcing cellular suicide (Rouleau et al., 2010). Several studies are 
actually looking into the second approach to see if PARP inhibitors can be utilized as therapeutic 
agents for single-agent or combination therapy as anticancer treatment. PARP inhibitors would 
work as therapeutic agents due to their capacity to block poly(ADP-Ribose) enzymes, these 
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enzymes help repair DNA damage. PARP inhibition assists with tumor growth limitation, and 
inhibition of angiogenesis (Rosado et al., 2013).  More recently PARP inhibitors have undergone 
clinical trials to assess their use against BRCA-defective cancer cells. PARP’s interaction with 
BRCA1 and BRCA2 proteins is crucial, if its excision repair was inhibited these types of cancer 
cells would be unable to repair DNA, thus leading to tumor death (Rosado et al., 2013). As trials 
continue to progress the medical applications for PARP inhibitors will broaden. While it is 
apparent that PARP plays an integral role in DNA-mediated cellular death, what role it plays is 
highly dependent upon the inducer of damage. The paradox is highly perplexing, in some instances 
of DNA damage typically lower scaled PARP plays a protective role in staving off cell death. In 
other instances when extensive DNA damage occurs PARP promotes cellular death. PARP’s 
ability to undertake duel-function roles is highly dependent upon cell type, DNA damage extent, 
cascade activation, and cellular target.  PARP as a consumer of energy (ATP / NAD) and nature 
as a DNA binding molecule are highly dependent: balance of which determines cellular survival 
(Herceg & Wang, 2001). 
Cardio toxicity of alkyling agents like cyclophosphamide are tied directly to the 
administrated treatment amount of a single dose vs. a lifetime dose response effect (Kumar, 
Dhankhar, Kar, Shrivastava, & Shrivastava, 2011).  Much like previous studies acrolein exposure 
for this study was assessed with a consistent cell density.  This is due to other assessments proving 
acrolein-induced toxicity was highly dependent upon dose received by each cell verses the 
treatment concentrated administered to each well. Additionally fold controls were used to assess a 
base line to establish cytotoxicity in treatment groups (Kern & Kehrer, 2002).  The range of 
treatment groups for acrolein were too high to be considered clinically relevant, but were good for 
assessing acute high-dose exposure at the cellular level. In terms of PARP analysis no inhibitor 
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intervention was applied, only time points of acrolein exposure were assessed. Poly (ADP-ribose) 
synthesis can only occur through members of the PARP family, primarily by PARP-1.  When 
DNA damage is present poly(ADP-Ribosyl)ation levels will be high, absent of DNA damage the 
levels will be very low (Bouchard et al., 2003). Analysis performed on PARP activity were used 
to help determine the extent of damage done through the treatment of acrolein. PARP activity 
increased as acrolein-treatment concentration increased to a point due to greater damage under 
taken by the cells. In higher acrolein-treatment groups activity dropped off, most likely due to 
inhibition of PARP to activation apoptotic pathways. Further analysis of acrolein exposure time-
points could give a broader understanding to the activation of PARP due to cytotoxicity.  Based 
on this analysis a trend was reviled that implied PARP activity would linearly decrease across all 
dose groups as acrolein exposure periods increased. Most likely this would be due to increased 
damages caused by the prolonged exposure periods.   
In terms of cytotoxic assessment this investigation had a few suggestions to offer for future 
assessment. For MTT analysis this investigation believes that a tighter standard deviation could be 
achieved through increasing the replication of trials. Additionally one analysis was discarded due 
to use of a pre-aliquoted DIQ being utilized. This aliquot had been stored at -20°C, its use showed 
no differences between vehicle and controls in any treatment groups. Further testing was 
performed using fresh 1,5-dihydroxyisoquinoline, each sequential analysis performed showed a 
protective factor. Thus it is recommended to prepare fresh PARP inhibitor prior to each trial as 
pre-aliquoted freezer storage impacted the ability for DIQ to reduce cytotoxic effects. When 
analyzing the AST assay this investigation proved the importance of insuring high protein in 
samples run for analysis. Poor performance in AST assays particularly from a poor signal strength 
can be attributed to loading with low protein (Huang et al., 2006). For future analysis it is 
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recommended to increase the protein load by increasing the cellular density and decreasing the 
replacement medium for which to collect the AST lysate.  This investigation used a 96-well treated 
plate, increasing to a 48-well or 24-well with a plating density of 50,000-75,000 cells per well 
should help all treatment groups to be read above detection.  When initially running AST analysis, 
a 24-hour wash out period was utilized, this resulted in a flat-line for AST signals, resulting in all 
treatment groups to fall below the detection limit. Two trial runs were performed to determine time 
points and lysate medium volumes.  Time points assessed were 2-hour, 4-hour, 6-hour, 8-hour 
respectively. A linear relationship was established with AST activity increasing until the 6-hour 
peak mark, with activity levels severely reduced at 8-hour reading. Additionally analysis was 
performed to determine the medium volume which would help concentrate AST the best, 35 µl 
was determined to be the best volume which would allow for adequate coverage of plate wells thus 
not skewing results by having cell death attributed to hypoxia vs. treatment.  Further analysis 
should be performed and investigate the levels of caspase-3 as it is a key marker for apoptosis.  
Cellular fate post-exposure to an alkylating agent is determined through the metabolic state of the 
cell. Inactivation of PARP by caspase-mediated cleave is responsible for initializing apoptosis 
having helped block the pathway of necrosis cell death (Jin & El-Deiry, 2005). Since caspase-3 is 
responsible for the cleavage of poly(ADP-Ribose) polymerase (PARP) during apoptosis, 
comparative measures of PARP, cleaved PARP, and caspase-3 activity could give a more in-depth 
analysis to the level of acrolein-induced cytotoxicity.  Cleaved PARP is induces apoptosis through 
chromatin condensation, membrane blebbing and DNA-fragmentation. (Cohen, 1997)  Western-
blot analysis was performed using Caspase-3 and PARP antibodies to determine MW present in 
samples. Positive identification of PARP, Cleaved-PARP and Caspase-3 occurred.  Digital 
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imaging of nitrocellulose membranes proved inadequate resolution for inclusion in this report. Use 
of more advanced imaging techniques in the future could produce a higher quality resolution.  
  
30 
 
 
 
 
CHAPTER FIVE: 
 
CONCLUSION 
This investigation assessed the role of the enzyme poly (ADP-ribose) polymerase (PARP) 
and PARP inhibitors in acrolein induced toxicity using the established toxicological H9c2 (2-1) 
cardiomyoblast in-vitro model. Through this analysis the characterization of PARP’s role in 
cytotoxicity was able to be determined. In low concentration PARP activation is suggestive of 
electrophilic damage of DNA. The inactivation of PARP at higher concentrations imitates 
apoptotic mediation through activation of caspase-3. Further analysis is needed to investigate 
PARP cleavage as a marker for apoptosis. Cytotoxic assessment showed that pre-incubation with 
a PARP inhibitor had a positive trend in increasing cellular viability in all treatment groups, 
statistically significant protection was reached in 25 µM & 50 µM treatment groups. MTT activity 
showed a positive trend across all treatment groups for increasing when DIQ groups were 
compared to vehicle groups. AST activity in isolated cell lysates for many lower treatment groups 
were unable produce a strong enough signal for data characterization of DIQ’s protective qualities 
due samples falling below detection limits. Higher treatment groups which were read above 
detection showed a positive trend when compared to vehicle groups, but statistical significance 
was unreached. Further analysis is needed to investigate methodological changes which could lead 
to an increase in signal strength for AST detection. Further analysis is also needed to investigate 
more clinically relevant levels of acrolein against longer exposure periods. Testing using the H9c2 
cardiomyocyte cell line represents an appropriate model for characterizing the role of PARP in 
acrolein-mediated cytotoxicity. 
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